Filing Flows › PTC Therapeutics (PTCT) › Q3 2025
PTC Therapeutics (PTCT) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
PTC Therapeutics (PTCT) reported revenue of $211M for the third quarter 2025 (Q3 2025), +7% from a year earlier and +18% from the quarter before. Operating margin was 1.4%, net earnings $15.9M (7.5% of revenue).
PTC Therapeutics, Q3 2025: revenue $211M (+7% year over year), operating margin 1.4%, net earnings $15.9M, operating cash flow −$66.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $211M | +18% | +7% |
| Operating profit | $3.0M | — | — |
| Net earnings | $15.9M | — | — |
| Operating cash flow | −$66.3M | — | — |
What changed
Revenue was $211.0M in Q3 2025, up 7% year over year and up 18% from the previous quarter. Royalty revenue was the largest line at 34% of revenue. Royalty revenue added $9.4M year over year (up 15%), 66% of the total change. Emflaza declined 32%.
Operating profit was $3.0M, a 1.4% margin (up 29.1 points year over year). Total costs fell 17% while revenue rose 7%. The fastest-growing cost line was Other operating costs (+45%). Net earnings were $15.9M.
Operating cash flow was −$66.3M. Non-cash charges added back $11.1M of depreciation and amortization and $19.4M of share-based compensation. Working capital and other items used $112.7M. Capital expenditures of $3.5M exceeded it, leaving free cash flow of −$69.8M.
Questions
What was PTC Therapeutics' revenue in the third quarter 2025?
PTC Therapeutics (PTCT) reported revenue of $211M for the third quarter 2025 (Q3 2025), +7% from a year earlier and +18% from the quarter before.
Was PTC Therapeutics profitable in the third quarter 2025?
Operating profit was $3.0M (1.4% of revenue) and net earnings $15.9M.
Source: PTC Therapeutics 10-Q on SEC EDGAR.